UK-based drug discovery group Storm Therapeutics has strengthened its scientific advisory board with the addition of Professor Mark Dawson.
As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells.
Dr Paul Leeson also joins the University of Cambridge spin-out, following 35 years’ experience of drug discovery and development in senior roles in pharmaceutical companies including GlaxoSmithKline, Merck Sharp and Dohme and AstraZeneca.
Keith Blundy, chief executive officer of Storm Therapeutics, said: “Mark’s expertise in epigenetics research will be invaluable as we advance selected targets into drug discovery, along with Paul’s long standing experience in drug discovery and development at big pharma will help Storm maximise the potential of our pipeline and harness the power of RNA epigenetics as a new area of important biology.”